The Key Role of <scp>COA6</scp> in Pancreatic Ductal Adenocarcinoma: Metabolic Reprogramming and Regulation of the Immune Microenvironment

Lai Jiang, Yuxuan Jiang, Xuancheng Zhou, Lexin Wang, Shengke Zhang, Cheng‐Lu Jiang, Hui Meng, Qingwen Hu, Yuheng Gu, Yong Fu, Ke Xu, Hao Chi, Xiaolin ZhongJournal of Cellular and Molecular Medicine 2025 · DOI

TL;DR

This study identifies COA6, a mitochondrial gene involved in oxidative phosphorylation (OXPHOS), as a key player in pancreatic ductal adenocarcinoma (PDAC). COA6's dysregulation fuels tumor growth, immune evasion, and therapeutic resistance by reprogramming cellular metabolism and influencing the tumor microenvironment (TME). Targeting COA6 presents a promising avenue for novel PDAC therapies.

What Problem Does This Paper Address?

Pancreatic ductal adenocarcinoma (PDAC) is notoriously difficult to treat due to its highly immunosuppressive tumor microenvironment (TME) and its ability to resist therapies. PDAC cells exhibit remarkable metabolic plasticity, shifting between glycolysis and oxidative phosphorylation (OXPHOS) to fuel their aggressive growth and survival. This metabolic reprogramming is a critical factor in their therapeutic resistance. Understanding the specific molecular mechanisms driving this metabolic adaptation and its impact on the TME is crucial for developing effective treatments. This paper aims to pinpoint key mitochondrial genes involved in PDAC's metabolic reprogramming and their role in shaping the TME, ultimately identifying potential therapeutic targets.

Methods

The researchers employed a multi-pronged approach:

  • Genomic and Transcriptomic Analysis: They utilized Summary-Based Mendelian Randomization (SMR) and HEIDI tests, integrating GWAS and eQTL data, to identify PDAC-associated mitochondrial genes.
  • Single-Cell RNA Sequencing (scRNA-seq): This allowed for a detailed characterization of cellular heterogeneity within PDAC tumors, identifying different cell types and their gene expression profiles. Tools like Seurat, CellChat, and CoGAPS were used for data processing, intercellular communication analysis, and pattern identification.
  • Spatial Transcriptomics: This technique provided insights into the spatial distribution of gene expression and cell types within the tumor tissue, revealing how COA6 expression is localized and interacts with its surroundings. Packages like spacexr and mistyr were employed for deconvolution and interaction analysis.
  • Functional Assays: Standard cell biology techniques were used to experimentally validate the role of COA6. These included CCK-8 assays for proliferation, colony formation assays for clonogenic ability, scratch wound healing and Transwell invasion assays for migration and invasion, and flow cytometry for apoptosis detection.
  • Bioinformatics and Computational Tools: Various tools were used for data analysis, including R packages, the Enhanced Algorithm for Systemic Immune Response Estimation (EaSIeR) for immune response prediction, and molecular docking for drug discovery.

Datasets

The study utilized several publicly available datasets:

  • GWAS data for pancreatic cancer: From the MRC IEU OpenGWAS (n=196,187).
  • Pancreatic tissue eQTL summary data: From the GTEx Consortium V8.
  • Single-cell sequencing data for pancreatic cancer: From the Gene Expression Omnibus (GEO) database (GSE155698 and GSE212966).
  • Spatial transcriptomics data: From the GEO database (GSE235315).
  • RNA-seq data for pancreatic cancer: From the UCSC Xena platform (TCGA cohort, 182 samples).
  • Mitochondrial-related gene list: From the MitoCarta 3.0 database.

Key Insights and Ideas

  • COA6 as a Central Player: The study strongly implicates COA6, a gene crucial for mitochondrial oxidative phosphorylation (OXPHOS), as a key driver of PDAC progression. Its upregulation in tumors, coupled with its functional impact, makes it a significant finding.
  • Metabolic Reprogramming Fuels Aggression: COA6's role in OXPHOS highlights how PDAC cells leverage mitochondrial metabolism not just for energy but also to enhance proliferation, migration, and resistance to therapies. This challenges the sole focus on glycolysis in PDAC research.
  • COA6 Shapes the Immune Microenvironment: Beyond its metabolic role, COA6 appears to actively modulate the TME, influencing immune cell infiltration and activity, potentially contributing to immune evasion.
  • Spatial Heterogeneity Matters: The spatial transcriptomics analysis reveals that COA6 expression is not uniform but concentrated in specific tumor regions, suggesting localized functional roles and interactions with surrounding cells.
  • Potential for Targeted Therapies: The identification of COA6 as a critical factor opens doors for developing novel therapeutic strategies, including small molecules that can target COA6 or its associated pathways.

Key Results

  • COA6 was significantly upregulated in PDAC tumors compared to normal tissues at both mRNA and protein levels.
  • Higher COA6 expression was associated with poorer disease-specific survival (DSS) and overall survival (OS) in PDAC patients.
  • Functional assays demonstrated that COA6 overexpression enhanced PDAC cell proliferation, migration, invasion, and chemoresistance. Conversely, COA6 knockdown suppressed these aggressive phenotypes and increased apoptosis.
  • Spatial analysis showed COA6 expression was enriched in tumor regions and positively correlated with tumor epithelial cells, CAFs, macrophages, and endothelial cells.
  • COA6 overexpression was linked to a significant reduction in key immune biomarkers (cytolytic activity, TLS, IFNy, T cell_inflamed, and chemokines), indicating immune suppression.
  • Enrichment analysis revealed that COA6 overexpression significantly upregulates OXPHOS, cell cycle regulation, and the p53 signaling pathway.
  • Tetrahydropalmatine was identified as a potential small-molecule inhibitor of COA6 through drug prediction and molecular docking.

Limitations and Future Work

  • Mechanistic Validation: While functional assays were performed, the authors acknowledge that further studies are needed to fully validate the mechanistic roles of identified genes, including COA6, through gene knockdown and overexpression models.
  • Underexplored Cell Populations: The study focused on COA6 and its interactions with key cell types. However, the roles of other stromal and non-cancerous cell populations in modulating mitochondrial function and the TME remain underexplored and warrant further investigation.
  • Development of Targeted Therapies: The authors emphasize the need for further research to develop COA6-targeted therapies, building upon the promising findings of this study. This includes exploring the therapeutic potential of identified compounds like tetrahydropalmatine.

Summary updated

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is characterised by immune hypo-responsiveness due to its complex, immunosuppressive tumour microenvironment (TME). Mitochondrial metabolic reprogramming allows PDAC cells to shift between glycolysis and oxidative phosphorylation (OXPHOS), supporting energy production and cellular viability, thus promoting tumour progression and therapeutic resistance. Mitochondrial genes associated with PDAC were identified using SMR/HEIDI analysis combined with MRC IEU OpenGWAS and GTEx V8 pancreatic eQTL databases. Single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics were used to explore cellular interactions and construct spatial interaction networks. Potential small-molecule compounds targeting the TME were identified through drug prediction and molecular docking. COA6 expression was silenced in SW1990 and PANC-1 cells to assess effects on cell proliferation, migration, invasion and apoptosis. COA6, a key gene in the OXPHOS pathway, was upregulated in PDAC tumours compared to normal tissues. Functional assays showed that COA6 overexpression enhanced proliferation, migration and chemoresistance of PDAC cells. COA6 modulates OXPHOS, influences the TME and promotes drug resistance in PDAC. It is a promising therapeutic target for improving clinical outcomes in PDAC patients. Further research is needed to develop COA6-targeted therapies.
BibTeX
@article{jiang2025key,
  author = {Lai Jiang and Yuxuan Jiang and Xuancheng Zhou and Lexin Wang and Shengke Zhang and Cheng‐Lu Jiang and Hui Meng and Qingwen Hu and Yuheng Gu and Yong Fu and Ke Xu and Hao Chi and Xiaolin Zhong},
  title = {{The Key Role of <scp>COA6</scp> in Pancreatic Ductal Adenocarcinoma: Metabolic Reprogramming and Regulation of the Immune Microenvironment}},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2025},
  doi = {10.1111/jcmm.70685},
}
Figure